(Q84675149)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22847245%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

title

Discontinuation of anti-TNF-α therapy in a Chinese cohort of patients with rheumatoid arthritis (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22847245%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference

Cheng-Tao Yang

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22847245%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Chang-Fu Kuo

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22847245%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Shue-Fen Luo

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22847245%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

Kuang-Hui Yu

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22847245%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

publication date

31 July 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22847245%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

published in

Clinical Rheumatology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22847245%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

volume

31

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22847245%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22847245%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

page(s)

1549-1557

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22847245%20AND%20SRC:MED&resulttype=core&format=json

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

9 February 2020

cites work

1 reference

12 December 2020

Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti–tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register

1 reference

12 December 2020

Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment

1 reference

12 December 2020

Mycobacterium tuberculosis in Taiwan

1 reference

12 December 2020

Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment

1 reference

12 December 2020

Autoimmune diseases induced by TNF-targeted therapies

1 reference

12 December 2020

1 reference

12 December 2020

Changes in immune function with age.

1 reference

12 December 2020

Risk of tuberculosis in patients with rheumatoid arthritis in Hong Kong--the role of TNF blockers in an area of high tuberculosis burden

1 reference

12 December 2020

The clinical application of etanercept in Chinese patients with rheumatic diseases

1 reference

12 December 2020

Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial

1 reference

12 December 2020

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.

1 reference

12 December 2020

Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events

1 reference

12 December 2020

Influence of age on the outcome of antitumour necrosis factor alpha therapy in rheumatoid arthritis

1 reference

12 December 2020

Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety

1 reference

12 December 2020

The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis

1 reference

12 December 2020

TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice

1 reference

12 December 2020

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis

1 reference

12 December 2020

Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management

1 reference

12 December 2020

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

12 December 2020

The antiinflammatory and antiviral effects of hydroxychloroquine in two patients with acquired immunodeficiency syndrome and active inflammatory arthritis

1 reference

12 December 2020

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

12 December 2020

The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis

1 reference

12 December 2020

Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis

1 reference

12 December 2020

The aging of the immune system

1 reference

12 December 2020

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

1 reference

12 December 2020

Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies.

1 reference

12 December 2020

The pathogenesis of rheumatoid arthritis

1 reference

12 December 2020

Elderly-onset rheumatoid arthritis

1 reference

12 December 2020

Association of infections and tuberculosis with antitumor necrosis factor alpha therapy.

1 reference

12 December 2020

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

1 reference

12 December 2020

Second-line antirheumatic drugs in the elderly with rheumatoid arthritis: a post hoc analysis of three controlled trials

1 reference

12 December 2020

Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study

1 reference

12 December 2020

Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy

1 reference

12 December 2020

10.1007/S10067-012-2047-8

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22847245%20AND%20SRC:MED&resulttype=core&format=json

9 February 2020

1 reference